晚期肝细胞癌的系统治疗:ASCO 指南更新
ASCO 专家组更新 2020 年晚期肝细胞癌系统治疗指南,系统评价纳入截至 2023 年 10 月发表的随机对照试验,新增 10 项符合标准的 RCT,并据此更新推荐,涉及一线、二线及三线治疗选择。
要点
- 一线可提供阿替利珠单抗+贝伐珠单抗或度伐利尤单抗+替西木单抗用于 Child-Pugh A 级、ECOG PS 0-1 的晚期肝细胞癌患者。
- 一线阿替利珠单抗+贝伐珠单抗后,二线可推荐 TKI、雷莫西尤单抗(AFP≥400 ng/mL)、度伐利尤单抗+替西木单抗或纳武利尤单抗+伊匹木单抗。
- Child-Pugh B 级晚期肝细胞癌患者推荐谨慎的系统治疗策略。
核心结论
- ASCO 更新晚期肝细胞癌系统治疗指南,新增 10 项 RCT 并更新一线、二线、三线治疗推荐。
研究设计与样本
- ASCO 召集专家组更新 2020 年肝细胞癌系统治疗指南,系统评价更新纳入截至 2023 年 10 月发表的随机对照试验。
主要发现
- 10 项新随机对照试验符合纳入标准并加入证据基础。
关键数值与推荐
- 一线可提供阿替利珠单抗+贝伐珠单抗或度伐利尤单抗+替西木单抗用于晚期肝细胞癌、Child-Pugh A 级肝病、ECOG PS 0-1 的患者。
- 存在上述治疗禁忌时,一线可提供索拉非尼、仑伐替尼或度伐利尤单抗。
- 一线阿替利珠单抗+贝伐珠单抗后,二线可推荐 TKI、雷莫西尤单抗(AFP≥400 ng/mL)、度伐利尤单抗+替西木单抗或纳武利尤单抗+伊匹木单抗用于合适候选者。
- 一线度伐利尤单抗+替西木单抗后,推荐二线 TKI。
- 一线索拉非尼或仑伐替尼后,二线选择包括卡博替尼、瑞戈非尼(既往耐受索拉非尼者)、雷莫西尤单抗(AFP≥400 ng/mL)、纳武利尤单抗+伊匹木单抗或度伐利尤单抗;一线未获得阿替利珠单抗+贝伐珠单抗或度伐利尤单抗+替西木单抗且无禁忌者,可考虑这些方案。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC). METHODS: ASCO convened an Expert Panel to update the 2020 guideline on systemic therapy for HCC. The panel updated the systematic review to include randomized controlled trials (RCTs) published through October 2023 and updated recommendations. RESULTS: Ten new RCTs met the inclusion criteria and were added to the evidence base. RECOMMENDATIONS: Atezolizumab + bevacizumab (atezo + bev) or durvalumab + tremelimumab (durva + treme) may be offered first-line for patients with advanced HCC, Child-Pugh class A liver disease, and Eastern Cooperative Oncology Group performance status 0-1. Where there are contraindications to these therapies, sorafenib, lenvatinib, or durvalumab may be offered first-line. Following first-line treatment with atezo + bev, second-line therapy with a tyrosine kinase inhibitor (TKI), ramucirumab (for patients with alpha-fetoprotein [AFP] ≥400 ng/mL), durva + treme, or nivolumab + ipilimumab (nivo + ipi) may be recommended for appropriate candidates. Following first-line therapy with durva + treme, second-line therapy with a TKI is recommended. Following first-line treatment with sorafenib or lenvatinib, second-line therapy options include cabozantinib, regorafenib for patients who previously tolerated sorafenib, ramucirumab (AFP ≥400 ng/mL), nivo + ipi, or durvalumab; atezo + bev or durva + treme may be considered for patients who did not have access to these therapies in the first-line setting, and do not have contraindications. Pembrolizumab or nivolumab are also options for appropriate patients following sorafenib or lenvatinib. Third-line therapy may be considered in Child-Pugh class A patients with good PS, using one of the agents listed previously that has a nonidentical mechanism of action with previously received therapy. A cautious approach to systemic therapy is recommended for patients with Child-Pugh class B advanced HCC. Further guidance on choosing between options is included within the guideline.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
引用
- Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. J Clin Oncol. 2024. PMID: 38502889. doi:10.1200/JCO.23.02745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。